Disclosure statement Supported by the National Institutes of Health (grant AI143965 [to M.C.D.]). Disclosure of potential conflict of interest: M. C. Dispenza has consulted and/or participated on advisory boards for Aditum Bio, ALK, Allakos, Blueprint Medicines, Guidepoint, GLG, Melinta Therapeutics, and Nurix Therapeutics and has received funding from AstraZeneca. The remaining author declares that she has no relevant conflicts of intertest.